Effect of nicorandil administration on cardiac burden and cardio-ankle vascular index after coronary intervention
Myocardial injury is a problem associated with percutaneous coronary intervention (PCI). This study aimed to clarify the role of nicorandil administration in preventing myocardial injury. This study included patients with stable angina who underwent PCI from November 2013 to June 2016. Of 58 consecu...
Gespeichert in:
Veröffentlicht in: | Heart and vessels 2020-12, Vol.35 (12), p.1664-1671 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1671 |
---|---|
container_issue | 12 |
container_start_page | 1664 |
container_title | Heart and vessels |
container_volume | 35 |
creator | Sato, Shuji Takahashi, Mao Mikamo, Hiroshi Kawazoe, Masayo Iizuka, Takuo Shimizu, Kazuhiro Noro, Mahito Shirai, Kohji |
description | Myocardial injury is a problem associated with percutaneous coronary intervention (PCI). This study aimed to clarify the role of nicorandil administration in preventing myocardial injury. This study included patients with stable angina who underwent PCI from November 2013 to June 2016. Of 58 consecutive patients, the first 20 patients received only saline infusion after PCI (control group); the other 38 patients received a continuous intravenous infusion of nicorandil and saline after PCI (nicorandil group). Troponin I and brain natriuretic peptide (BNP) levels were measured. Vascular parameters, such as blood pressure (BP), cardiac output, cardio-ankle vascular index (CAVI), and estimated systemic vascular resistance (eSVR), were measured. Troponin I of both groups increased 12 h after PCI. Changes in BNP levels between immediately after PCI and 12 h after PCI were significantly higher in the control than in the nicorandil group (10.8 ± 44.2 vs. − 2.6 ± 14.6 pg/ml,
p
= 0.04). In the nicorandil group, BP, eSVR, and CAVI decreased significantly at 12 h after PCI compared with those immediately after PCI (
p
|
doi_str_mv | 10.1007/s00380-020-01650-9 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7595970</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2473804524</sourcerecordid><originalsourceid>FETCH-LOGICAL-c564t-7a9f8a8846b94bb3dc79226fcbf8efa9705459e24faa8b3074ca07c49e410e413</originalsourceid><addsrcrecordid>eNp9kUFPHiEQhklTU7_a_gEPhqTnrcDCslxMGmNbExMv9kxmWVDsfqCw-6X99x1da-3FhAlh5p1nJryEHHL2mTOmjytjbc8aJjB4p1hj3pAN77hqhNLtW7JhhrOmb4XeJ-9rvWWMK8PNO7LfokCoTm_I_VkI3s00B5qiywXSGCcK4zamWOcCc8yJ4nFQxgiODksZfaIoW1O5gfRz8nQH1S0TFBrT6H9RCLMvFHk5QfmNSXzufHqgfSB7AabqPz7dB-TH17Or0-_NxeW389MvF41TnZwbDSb00PeyG4wchnZ02gjRBTeE3gcwmimpjBcyAPRDy7R0wLSTxkvOMNoDcrJy75Zh60eH0wtM9q7ELa5kM0T7fyXFG3udd1YroxCPgE9PgJLvF19ne5uXknBnK6TGn5dKSFSJVeVKrrX48DyBM_tgk11tsmiTfbTJGmw6ernbc8tfX1DQroKKpXTty7_Zr2D_ACcxoQI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2473804524</pqid></control><display><type>article</type><title>Effect of nicorandil administration on cardiac burden and cardio-ankle vascular index after coronary intervention</title><source>MEDLINE</source><source>SpringerLink</source><creator>Sato, Shuji ; Takahashi, Mao ; Mikamo, Hiroshi ; Kawazoe, Masayo ; Iizuka, Takuo ; Shimizu, Kazuhiro ; Noro, Mahito ; Shirai, Kohji</creator><creatorcontrib>Sato, Shuji ; Takahashi, Mao ; Mikamo, Hiroshi ; Kawazoe, Masayo ; Iizuka, Takuo ; Shimizu, Kazuhiro ; Noro, Mahito ; Shirai, Kohji</creatorcontrib><description>Myocardial injury is a problem associated with percutaneous coronary intervention (PCI). This study aimed to clarify the role of nicorandil administration in preventing myocardial injury. This study included patients with stable angina who underwent PCI from November 2013 to June 2016. Of 58 consecutive patients, the first 20 patients received only saline infusion after PCI (control group); the other 38 patients received a continuous intravenous infusion of nicorandil and saline after PCI (nicorandil group). Troponin I and brain natriuretic peptide (BNP) levels were measured. Vascular parameters, such as blood pressure (BP), cardiac output, cardio-ankle vascular index (CAVI), and estimated systemic vascular resistance (eSVR), were measured. Troponin I of both groups increased 12 h after PCI. Changes in BNP levels between immediately after PCI and 12 h after PCI were significantly higher in the control than in the nicorandil group (10.8 ± 44.2 vs. − 2.6 ± 14.6 pg/ml,
p
= 0.04). In the nicorandil group, BP, eSVR, and CAVI decreased significantly at 12 h after PCI compared with those immediately after PCI (
p
< 0.0001), whereas no change was observed in the control group. In a single linear analysis, the change in BP (
r
= 0.36,
p
< 0.01) and nicorandil administration (
r
= − 0.47,
p
< 0.001) was significantly correlated with the change in CAVI, multiple regression analysis revealed that the changes in CO and eSVR were significant contributing factors for the changes in CAVI. PCI could result in myocardial injury and/or cardiac burden in patients with stable angina. Nicorandil administration after PCI may be effective in relieving the burden by decreasing arterial stiffness (CAVI).</description><identifier>ISSN: 0910-8327</identifier><identifier>EISSN: 1615-2573</identifier><identifier>DOI: 10.1007/s00380-020-01650-9</identifier><identifier>PMID: 32572567</identifier><language>eng</language><publisher>Tokyo: Springer Japan</publisher><subject>Aged ; Angina ; Angina pectoris ; Angina, Stable - diagnostic imaging ; Angina, Stable - physiopathology ; Angina, Stable - therapy ; Ankle ; Biomedical Engineering and Bioengineering ; Blood pressure ; Brain natriuretic peptide ; Calcium-binding protein ; Cardiac output ; Cardiac Surgery ; Cardiology ; Coronary Artery Disease - diagnostic imaging ; Coronary Artery Disease - physiopathology ; Coronary Artery Disease - therapy ; Female ; Heart ; Heart Diseases - diagnostic imaging ; Heart Diseases - etiology ; Heart Diseases - physiopathology ; Heart Diseases - prevention & control ; Hemodynamics - drug effects ; Humans ; Infusions, Intravenous ; Injury prevention ; Intravenous administration ; Intravenous infusion ; Linear analysis ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Multiple regression analysis ; Nicorandil - administration & dosage ; Nicorandil - adverse effects ; Original ; Original Article ; Percutaneous Coronary Intervention - adverse effects ; Stiffness ; Time Factors ; Treatment Outcome ; Troponin ; Troponin I ; Vascular Stiffness - drug effects ; Vascular Surgery ; Vasodilator Agents - administration & dosage ; Vasodilator Agents - adverse effects</subject><ispartof>Heart and vessels, 2020-12, Vol.35 (12), p.1664-1671</ispartof><rights>The Author(s) 2020</rights><rights>The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c564t-7a9f8a8846b94bb3dc79226fcbf8efa9705459e24faa8b3074ca07c49e410e413</citedby><cites>FETCH-LOGICAL-c564t-7a9f8a8846b94bb3dc79226fcbf8efa9705459e24faa8b3074ca07c49e410e413</cites><orcidid>0000-0002-6386-8670</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00380-020-01650-9$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00380-020-01650-9$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,27915,27916,41479,42548,51310</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32572567$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sato, Shuji</creatorcontrib><creatorcontrib>Takahashi, Mao</creatorcontrib><creatorcontrib>Mikamo, Hiroshi</creatorcontrib><creatorcontrib>Kawazoe, Masayo</creatorcontrib><creatorcontrib>Iizuka, Takuo</creatorcontrib><creatorcontrib>Shimizu, Kazuhiro</creatorcontrib><creatorcontrib>Noro, Mahito</creatorcontrib><creatorcontrib>Shirai, Kohji</creatorcontrib><title>Effect of nicorandil administration on cardiac burden and cardio-ankle vascular index after coronary intervention</title><title>Heart and vessels</title><addtitle>Heart Vessels</addtitle><addtitle>Heart Vessels</addtitle><description>Myocardial injury is a problem associated with percutaneous coronary intervention (PCI). This study aimed to clarify the role of nicorandil administration in preventing myocardial injury. This study included patients with stable angina who underwent PCI from November 2013 to June 2016. Of 58 consecutive patients, the first 20 patients received only saline infusion after PCI (control group); the other 38 patients received a continuous intravenous infusion of nicorandil and saline after PCI (nicorandil group). Troponin I and brain natriuretic peptide (BNP) levels were measured. Vascular parameters, such as blood pressure (BP), cardiac output, cardio-ankle vascular index (CAVI), and estimated systemic vascular resistance (eSVR), were measured. Troponin I of both groups increased 12 h after PCI. Changes in BNP levels between immediately after PCI and 12 h after PCI were significantly higher in the control than in the nicorandil group (10.8 ± 44.2 vs. − 2.6 ± 14.6 pg/ml,
p
= 0.04). In the nicorandil group, BP, eSVR, and CAVI decreased significantly at 12 h after PCI compared with those immediately after PCI (
p
< 0.0001), whereas no change was observed in the control group. In a single linear analysis, the change in BP (
r
= 0.36,
p
< 0.01) and nicorandil administration (
r
= − 0.47,
p
< 0.001) was significantly correlated with the change in CAVI, multiple regression analysis revealed that the changes in CO and eSVR were significant contributing factors for the changes in CAVI. PCI could result in myocardial injury and/or cardiac burden in patients with stable angina. Nicorandil administration after PCI may be effective in relieving the burden by decreasing arterial stiffness (CAVI).</description><subject>Aged</subject><subject>Angina</subject><subject>Angina pectoris</subject><subject>Angina, Stable - diagnostic imaging</subject><subject>Angina, Stable - physiopathology</subject><subject>Angina, Stable - therapy</subject><subject>Ankle</subject><subject>Biomedical Engineering and Bioengineering</subject><subject>Blood pressure</subject><subject>Brain natriuretic peptide</subject><subject>Calcium-binding protein</subject><subject>Cardiac output</subject><subject>Cardiac Surgery</subject><subject>Cardiology</subject><subject>Coronary Artery Disease - diagnostic imaging</subject><subject>Coronary Artery Disease - physiopathology</subject><subject>Coronary Artery Disease - therapy</subject><subject>Female</subject><subject>Heart</subject><subject>Heart Diseases - diagnostic imaging</subject><subject>Heart Diseases - etiology</subject><subject>Heart Diseases - physiopathology</subject><subject>Heart Diseases - prevention & control</subject><subject>Hemodynamics - drug effects</subject><subject>Humans</subject><subject>Infusions, Intravenous</subject><subject>Injury prevention</subject><subject>Intravenous administration</subject><subject>Intravenous infusion</subject><subject>Linear analysis</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Multiple regression analysis</subject><subject>Nicorandil - administration & dosage</subject><subject>Nicorandil - adverse effects</subject><subject>Original</subject><subject>Original Article</subject><subject>Percutaneous Coronary Intervention - adverse effects</subject><subject>Stiffness</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Troponin</subject><subject>Troponin I</subject><subject>Vascular Stiffness - drug effects</subject><subject>Vascular Surgery</subject><subject>Vasodilator Agents - administration & dosage</subject><subject>Vasodilator Agents - adverse effects</subject><issn>0910-8327</issn><issn>1615-2573</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><recordid>eNp9kUFPHiEQhklTU7_a_gEPhqTnrcDCslxMGmNbExMv9kxmWVDsfqCw-6X99x1da-3FhAlh5p1nJryEHHL2mTOmjytjbc8aJjB4p1hj3pAN77hqhNLtW7JhhrOmb4XeJ-9rvWWMK8PNO7LfokCoTm_I_VkI3s00B5qiywXSGCcK4zamWOcCc8yJ4nFQxgiODksZfaIoW1O5gfRz8nQH1S0TFBrT6H9RCLMvFHk5QfmNSXzufHqgfSB7AabqPz7dB-TH17Or0-_NxeW389MvF41TnZwbDSb00PeyG4wchnZ02gjRBTeE3gcwmimpjBcyAPRDy7R0wLSTxkvOMNoDcrJy75Zh60eH0wtM9q7ELa5kM0T7fyXFG3udd1YroxCPgE9PgJLvF19ne5uXknBnK6TGn5dKSFSJVeVKrrX48DyBM_tgk11tsmiTfbTJGmw6ernbc8tfX1DQroKKpXTty7_Zr2D_ACcxoQI</recordid><startdate>20201201</startdate><enddate>20201201</enddate><creator>Sato, Shuji</creator><creator>Takahashi, Mao</creator><creator>Mikamo, Hiroshi</creator><creator>Kawazoe, Masayo</creator><creator>Iizuka, Takuo</creator><creator>Shimizu, Kazuhiro</creator><creator>Noro, Mahito</creator><creator>Shirai, Kohji</creator><general>Springer Japan</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>P64</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-6386-8670</orcidid></search><sort><creationdate>20201201</creationdate><title>Effect of nicorandil administration on cardiac burden and cardio-ankle vascular index after coronary intervention</title><author>Sato, Shuji ; Takahashi, Mao ; Mikamo, Hiroshi ; Kawazoe, Masayo ; Iizuka, Takuo ; Shimizu, Kazuhiro ; Noro, Mahito ; Shirai, Kohji</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c564t-7a9f8a8846b94bb3dc79226fcbf8efa9705459e24faa8b3074ca07c49e410e413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Aged</topic><topic>Angina</topic><topic>Angina pectoris</topic><topic>Angina, Stable - diagnostic imaging</topic><topic>Angina, Stable - physiopathology</topic><topic>Angina, Stable - therapy</topic><topic>Ankle</topic><topic>Biomedical Engineering and Bioengineering</topic><topic>Blood pressure</topic><topic>Brain natriuretic peptide</topic><topic>Calcium-binding protein</topic><topic>Cardiac output</topic><topic>Cardiac Surgery</topic><topic>Cardiology</topic><topic>Coronary Artery Disease - diagnostic imaging</topic><topic>Coronary Artery Disease - physiopathology</topic><topic>Coronary Artery Disease - therapy</topic><topic>Female</topic><topic>Heart</topic><topic>Heart Diseases - diagnostic imaging</topic><topic>Heart Diseases - etiology</topic><topic>Heart Diseases - physiopathology</topic><topic>Heart Diseases - prevention & control</topic><topic>Hemodynamics - drug effects</topic><topic>Humans</topic><topic>Infusions, Intravenous</topic><topic>Injury prevention</topic><topic>Intravenous administration</topic><topic>Intravenous infusion</topic><topic>Linear analysis</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Multiple regression analysis</topic><topic>Nicorandil - administration & dosage</topic><topic>Nicorandil - adverse effects</topic><topic>Original</topic><topic>Original Article</topic><topic>Percutaneous Coronary Intervention - adverse effects</topic><topic>Stiffness</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Troponin</topic><topic>Troponin I</topic><topic>Vascular Stiffness - drug effects</topic><topic>Vascular Surgery</topic><topic>Vasodilator Agents - administration & dosage</topic><topic>Vasodilator Agents - adverse effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sato, Shuji</creatorcontrib><creatorcontrib>Takahashi, Mao</creatorcontrib><creatorcontrib>Mikamo, Hiroshi</creatorcontrib><creatorcontrib>Kawazoe, Masayo</creatorcontrib><creatorcontrib>Iizuka, Takuo</creatorcontrib><creatorcontrib>Shimizu, Kazuhiro</creatorcontrib><creatorcontrib>Noro, Mahito</creatorcontrib><creatorcontrib>Shirai, Kohji</creatorcontrib><collection>SpringerOpen</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Heart and vessels</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sato, Shuji</au><au>Takahashi, Mao</au><au>Mikamo, Hiroshi</au><au>Kawazoe, Masayo</au><au>Iizuka, Takuo</au><au>Shimizu, Kazuhiro</au><au>Noro, Mahito</au><au>Shirai, Kohji</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of nicorandil administration on cardiac burden and cardio-ankle vascular index after coronary intervention</atitle><jtitle>Heart and vessels</jtitle><stitle>Heart Vessels</stitle><addtitle>Heart Vessels</addtitle><date>2020-12-01</date><risdate>2020</risdate><volume>35</volume><issue>12</issue><spage>1664</spage><epage>1671</epage><pages>1664-1671</pages><issn>0910-8327</issn><eissn>1615-2573</eissn><abstract>Myocardial injury is a problem associated with percutaneous coronary intervention (PCI). This study aimed to clarify the role of nicorandil administration in preventing myocardial injury. This study included patients with stable angina who underwent PCI from November 2013 to June 2016. Of 58 consecutive patients, the first 20 patients received only saline infusion after PCI (control group); the other 38 patients received a continuous intravenous infusion of nicorandil and saline after PCI (nicorandil group). Troponin I and brain natriuretic peptide (BNP) levels were measured. Vascular parameters, such as blood pressure (BP), cardiac output, cardio-ankle vascular index (CAVI), and estimated systemic vascular resistance (eSVR), were measured. Troponin I of both groups increased 12 h after PCI. Changes in BNP levels between immediately after PCI and 12 h after PCI were significantly higher in the control than in the nicorandil group (10.8 ± 44.2 vs. − 2.6 ± 14.6 pg/ml,
p
= 0.04). In the nicorandil group, BP, eSVR, and CAVI decreased significantly at 12 h after PCI compared with those immediately after PCI (
p
< 0.0001), whereas no change was observed in the control group. In a single linear analysis, the change in BP (
r
= 0.36,
p
< 0.01) and nicorandil administration (
r
= − 0.47,
p
< 0.001) was significantly correlated with the change in CAVI, multiple regression analysis revealed that the changes in CO and eSVR were significant contributing factors for the changes in CAVI. PCI could result in myocardial injury and/or cardiac burden in patients with stable angina. Nicorandil administration after PCI may be effective in relieving the burden by decreasing arterial stiffness (CAVI).</abstract><cop>Tokyo</cop><pub>Springer Japan</pub><pmid>32572567</pmid><doi>10.1007/s00380-020-01650-9</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-6386-8670</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0910-8327 |
ispartof | Heart and vessels, 2020-12, Vol.35 (12), p.1664-1671 |
issn | 0910-8327 1615-2573 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7595970 |
source | MEDLINE; SpringerLink |
subjects | Aged Angina Angina pectoris Angina, Stable - diagnostic imaging Angina, Stable - physiopathology Angina, Stable - therapy Ankle Biomedical Engineering and Bioengineering Blood pressure Brain natriuretic peptide Calcium-binding protein Cardiac output Cardiac Surgery Cardiology Coronary Artery Disease - diagnostic imaging Coronary Artery Disease - physiopathology Coronary Artery Disease - therapy Female Heart Heart Diseases - diagnostic imaging Heart Diseases - etiology Heart Diseases - physiopathology Heart Diseases - prevention & control Hemodynamics - drug effects Humans Infusions, Intravenous Injury prevention Intravenous administration Intravenous infusion Linear analysis Male Medicine Medicine & Public Health Middle Aged Multiple regression analysis Nicorandil - administration & dosage Nicorandil - adverse effects Original Original Article Percutaneous Coronary Intervention - adverse effects Stiffness Time Factors Treatment Outcome Troponin Troponin I Vascular Stiffness - drug effects Vascular Surgery Vasodilator Agents - administration & dosage Vasodilator Agents - adverse effects |
title | Effect of nicorandil administration on cardiac burden and cardio-ankle vascular index after coronary intervention |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T19%3A56%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20nicorandil%20administration%20on%20cardiac%20burden%20and%20cardio-ankle%20vascular%20index%20after%20coronary%20intervention&rft.jtitle=Heart%20and%20vessels&rft.au=Sato,%20Shuji&rft.date=2020-12-01&rft.volume=35&rft.issue=12&rft.spage=1664&rft.epage=1671&rft.pages=1664-1671&rft.issn=0910-8327&rft.eissn=1615-2573&rft_id=info:doi/10.1007/s00380-020-01650-9&rft_dat=%3Cproquest_pubme%3E2473804524%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2473804524&rft_id=info:pmid/32572567&rfr_iscdi=true |